Curative Biosciences Inc
Curative Biosciences, Inc. focuses on developing and commercializing therapeutics using hemp-derived Cannabidiol. It intends to manufacture and market natural health products and operate in the medical cannabis industry. The company was formerly known as Amaize Beverage Corporation and changed its name to Curative Biosciences, Inc. in August 2017. Curative Biosciences, Inc. was founded in 2009 an… Read more
Curative Biosciences Inc (CBDX) - Total Assets
Latest total assets as of March 2018: $13.87K USD
Based on the latest financial reports, Curative Biosciences Inc (CBDX) holds total assets worth $13.87K USD as of March 2018.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Curative Biosciences Inc - Total Assets Trend (2014–2017)
This chart illustrates how Curative Biosciences Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Curative Biosciences Inc - Asset Composition Analysis
Current Asset Composition (June 2017)
Curative Biosciences Inc's total assets of $13.87K consist of 0.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $2.27K | 100.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2017)
This chart illustrates how Curative Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Curative Biosciences Inc's current assets represent 0.0% of total assets in 2017, a decrease from 23.0% in 2014.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2017, down from 11.6% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 7.0% in 2014.
- Asset Diversification: The largest asset category is property, plant & equipment at 100.0% of total assets.
Curative Biosciences Inc Competitors by Total Assets
Key competitors of Curative Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Curative Biosciences Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Curative Biosciences Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Curative Biosciences Inc is currently not profitable relative to its asset base.
Curative Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.00 | - | - |
| Quick Ratio | 0.00 | - | - |
| Cash Ratio | 0.00 | - | - |
| Working Capital | $-718.56K | - | - |
Curative Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Curative Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.33 |
| Asset Growth Rate (YoY) | -55.7% |
| Total Assets | $2.27K |
| Market Capitalization | $750.15 USD |
Valuation Analysis
Below Book Valuation: The market values Curative Biosciences Inc's assets below their book value (0.33 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Curative Biosciences Inc's assets decreased by 55.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Curative Biosciences Inc (2014–2017)
The table below shows the annual total assets of Curative Biosciences Inc from 2014 to 2017.
| Year | Total Assets | Change |
|---|---|---|
| 2017-06-30 | $2.27K | -55.70% |
| 2016-06-30 | $5.11K | -48.67% |
| 2015-06-30 | $9.96K | -36.35% |
| 2014-06-30 | $15.65K | -- |